Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned a consensus recommendation of “Hold” from the twenty-five ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $113.75.
Several research firms have issued reports on MRNA. Bank of America lifted their target price on Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. The Goldman Sachs Group increased their price target on shares of Moderna from $137.00 to $195.00 and gave the company a “neutral” rating in a research report on Monday, November 9th. Jefferies Financial Group restated a “hold” rating and issued a $150.00 price target (up from $60.00) on shares of Moderna in a report on Wednesday, August 19th. Piper Sandler restated an “overweight” rating and issued a $305.00 price target (up from $230.00) on shares of Moderna in a report on Monday, November 9th. Finally, Citigroup reaffirmed a “sell” rating on shares of Moderna in a research report on Friday, October 23rd.
Get Our Latest Analysis on MRNA
Insider Activity at Moderna
In other news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock valued at $33,875,904 over the last 90 days. Insiders own 10.80% of the company’s stock.
Institutional Investors Weigh In On Moderna
Several institutional investors have recently added to or reduced their stakes in MRNA. Worldquant Millennium Advisors LLC acquired a new stake in Moderna during the 3rd quarter worth about $36,933,000. Toronto Dominion Bank increased its holdings in Moderna by 36.6% in the 3rd quarter. Toronto Dominion Bank now owns 62,732 shares of the company’s stock worth $12,080,000 after buying an additional 16,810 shares during the period. Waterloo Capital L.P. acquired a new position in Moderna in the 3rd quarter worth approximately $219,000. State of Tennessee Department of Treasury increased its holdings in Moderna by 21.7% in the 3rd quarter. State of Tennessee Department of Treasury now owns 82,511 shares of the company’s stock worth $15,889,000 after buying an additional 14,689 shares during the period. Finally, Bank OZK purchased a new position in Moderna during the 3rd quarter worth approximately $1,775,000. Institutional investors and hedge funds own 75.33% of the company’s stock.
Moderna Stock Performance
Moderna stock opened at $215.27 on Friday. The business has a fifty day moving average of $203.06 and a two-hundred day moving average of $97.26. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. Moderna has a twelve month low of $22.28 and a twelve month high of $280.80.
Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The business’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.51) EPS. On average, research analysts predict that Moderna will post -5.14 EPS for the current fiscal year.
Moderna Company Profile
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Moderna
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
